开云app官网登录入口网页版-官方正版

#BRAF抑制剂#

9篇内容 | 1363人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2191833, encodeId=4d37219183325, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=大咖谈 | BRAF突变CRC治疗文献分享, objectType=article, longId=815657, objectId=565381565e41, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/filling-medical-history-XZB9RVX.jpg, objectUrl=/article/show_article.do?id=565381565e41, replyNumber=0, likeNumber=62, createdTime=2024-03-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=565381565e41, moduleTitle=大咖谈 | BRAF突变CRC治疗文献分享, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=565381565e41)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2171667, encodeId=6f7321e166706, content=<a href='/topic/show?id=78aa999190f' target=_blank style='color:#2F92EE;'>#靶向治疗#</a> <a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a> <a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a> <a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=大咖谈 | BRAF突变实体瘤治疗进展, objectType=article, longId=802724, objectId=4834802e2470, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=4834802e2470, replyNumber=0, likeNumber=90, createdTime=2023-11-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4834802e2470, moduleTitle=大咖谈 | BRAF突变实体瘤治疗进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4834802e2470)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1530195, encodeId=361515301951e, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, objectType=article, longId=727754, objectId=ef63e277540f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef63e277540f, replyNumber=0, likeNumber=61, createdTime=2022-05-26, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef63e277540f, moduleTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ef63e277540f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530194, encodeId=ebb21530194b3, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, objectType=article, longId=209533, objectId=155e209533de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=155e209533de, replyNumber=0, likeNumber=84, createdTime=2021-04-05, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=155e209533de, moduleTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=155e209533de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530193, encodeId=695315301936c, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, objectType=article, longId=200028, objectId=1381200028b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1381200028b8, replyNumber=0, likeNumber=72, createdTime=2020-08-30, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1381200028b8, moduleTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1381200028b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530192, encodeId=2bfe15301924c, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, objectType=article, longId=195394, objectId=51fd195394e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51fd195394e1, replyNumber=0, likeNumber=65, createdTime=2020-06-07, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51fd195394e1, moduleTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=51fd195394e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530191, encodeId=da081530191c5, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, objectType=article, longId=191946, objectId=1e43191946c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e43191946c0, replyNumber=0, likeNumber=64, createdTime=2020-04-11, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e43191946c0, moduleTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e43191946c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530190, encodeId=7abb15301903c, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果, objectType=article, longId=186510, objectId=455918651038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=455918651038, replyNumber=0, likeNumber=84, createdTime=2020-01-20, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=455918651038, moduleTitle=BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=455918651038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530189, encodeId=dc4e153018963, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可, objectType=article, longId=183896, objectId=82f1183896b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82f1183896b9, replyNumber=0, likeNumber=82, createdTime=2019-12-02, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82f1183896b9, moduleTitle=璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=82f1183896b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530188, encodeId=45b01530188e2, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测, objectType=article, longId=138830, objectId=1e7b1388303f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e7b1388303f, replyNumber=0, likeNumber=80, createdTime=2018-05-24, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e7b1388303f, moduleTitle=CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e7b1388303f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530187, encodeId=95c8153018ead, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, objectTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, objectType=article, longId=137007, objectId=d64a13e007c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64a13e007c3, replyNumber=0, likeNumber=74, createdTime=2018-05-04, rootId=0, userName=hjwang83, userId=292d12051665, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64a13e007c3, moduleTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d64a13e007c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

BRAF抑制剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #BRAF抑制剂#

大咖谈 | BRAF突变CRC治疗文献分享

2024-03-07发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#靶向治疗# #免疫治疗# #BRAF抑制剂# #BRAF突变#

大咖谈 | BRAF突变实体瘤治疗进展

2023-11-29发表于上海

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效

2022-05-26

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元

2021-04-05

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性

2020-08-30

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌

2020-06-07

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌

2020-04-11

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果

2020-01-20

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可

2019-12-02

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测

2018-05-24

hjwang83 (审核中...)

前往app查看评论内容

#BRAF抑制剂#

诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤

2018-05-04

科室
- - 订阅+
  - 更多科室
工具
服务